An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that CEO Harout Semerjian will present at the H.C. Wainwright & Co 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. The presentation will be accessible on the company's website starting September 13 at 7:00 a.m. EDT for 30 days. GlycoMimetics, a clinical-stage biotechnology firm, focuses on developing glycobiology-based therapies for cancers and inflammatory diseases, with its lead drug candidate, uproleselan, currently in a Phase 3 trial for relapsed/refractory acute myeloid leukemia.
Positive
None.
Negative
None.
ROCKVILLE, Md.--(BUSINESS WIRE)--
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Harout Semerjian will present at the upcoming H.C. Wainwright & Co 23rd Annual Global Investment Virtual Conference taking place September 13-15, 2021. The presentation will be available on the company’s website at the “Investors” tab for 30 days, beginning Monday, September 13 at 7:00 a.m. EDT.
GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company’s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, that alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. The Company’s lead drug candidate, uproleselan, has received Breakthrough Therapy Designation in the U.S. and China and is undergoing evaluation across a range of patient populations, including a Phase 3 trial in relapsed/refractory AML. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
When will GlycoMimetics present at the H.C. Wainwright & Co conference?
GlycoMimetics will present at the H.C. Wainwright & Co 23rd Annual Global Investment Virtual Conference from September 13-15, 2021.
How can I access the GlycoMimetics presentation from the conference?
The presentation will be available on the GlycoMimetics website under the 'Investors' tab starting September 13 at 7:00 a.m. EDT for 30 days.
What is the focus of GlycoMimetics, Inc.?
GlycoMimetics is focused on discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia, and inflammatory diseases.
What is GlycoMimetics' lead drug candidate?
GlycoMimetics' lead drug candidate is uproleselan, which has received Breakthrough Therapy Designation in the U.S. and China.
Where is GlycoMimetics located?
GlycoMimetics is located in Rockville, MD, in the BioHealth Capital Region.
